1. INTRODUCTION {#sec1}
===============

In the highly active anti-retroviral therapy (HAART) era, the HIV epidemic is expanding among individuals in the HIV risk category men who have sex with men (MSM); this has been recognized in high-income countries, including Australia, France, the United Kingdom, and the United States \[[@r1]-[@r3]\]. In Canada, the proportion of HIV cases that are categorized as MSM has decreased over the years but it still represents the largest group of HIV infected adults (≥ 15 years old) \[[@r4]\]. In 2016, 44.1% of adult HIV cases with a known exposure category were MSM \[[@r4]\].

HIV-infected people with weakened immune systems are vulnerable to opportunistic infections (OIs) \[[@r5]\]. More specifically, HIV-infected persons who have CD4+ count less than 500 are at higher risk for OIs \[[@r5]\]. The Centre for Disease Control and Prevention (CDC) developed a list of OIs that are considered as AIDS-defining conditions (ADC) or AIDS-defining illness (ADI) \[[@r6]\]. Kaposi's sarcoma (KS), non-Hodgkin lymphoma (NHL), and cervical cancer are ADC based on the list. These ADC are defined as AIDS-defining cancer or cancer-related AIDS \[[@r7]-[@r9]\].

The risk of these ADC is higher among HIV-infected individuals \[[@r10]\].

Cancer and HIV have been associated since 1981 when KS was identified for the first time in an immunosuppressed white MSM \[[@r11]\]. HIV-infected people with a weak immune system have also been diagnosed with NHL and invasive cervical cancer \[[@r7], [@r11]\]. Although the incidence of NHL and KS among HIV-infected individuals have decreased in the HAART era, they remain higher in HIV-infected individuals compared to HIV uninfected people \[[@r12], [@r13]\]. In a multi-state, population-based study in the USA by Hernández-Ramírez, the incidence rate of cancer-related AIDS was 2.1/1000 person-years over the follow-up period of 1996 to 2012 \[[@r14]\]. Shiels *et al.*, in a sample of American military personnel or their beneficiaries, found that the risk of developing cancer-AIDS and non-cancer AIDS among HIV positive individuals in the HAART era was 2.6/1000 person-years and 13.1/1000 person-years respectively \[[@r15]\]. By specific cancer AIDS malignancy type, Alberta HIV patients in the HAART era were found to have 4 cases of KS per 1000 person-years and 2 cases of NHL per 1000 person-years, respectively \[[@r16]\]. Among HIV patients in British Columbia, 123 of 4918 (2.5%) developed cancer AIDS when followed through 1996 to 2008 \[[@r17]\].

In this study, the objective is to examine the effect of covariates on survival outcomes. However, survival outcome can be associated with time-dependent longitudinal measurements/outcome which should be considered when studying the effect of covariates on survival outcomes \[[@r18]-[@r22]\]. Joint modeling of longitudinal and survival outcomes considers this association by modeling two outcomes simultaneously and provides more efficient, almost unbiased estimates \[[@r20], [@r23]-[@r26]\]. In joint modeling, two models are joined; a model for longitudinal measurements or outcome and a model for survival outcome. Using this approach, one can study the effect of covariates on the longitudinal outcome, the survival outcome or both. It is also possible to examine the effect of the longitudinal outcome on survival outcome.

There were two survival outcomes in this study: cancer AIDS and, non-cancer AIDS, which are considered as competing risks of each other \[[@r15], [@r27], [@r28]\]. Hence, we apply the joint modeling method with competing risks \[[@r29]-[@r35]\].

2. METHODS {#sec2}
==========

2.1. Study Population {#sec2.1}
---------------------

HAART has been widely available since 1997 \[[@r16], [@r36]\]. From the Ontario HIV Treatment Network Cohort Study (OCS), individuals whose HIV-positive year was 1997 or later (*i.e.* HAART era) and were a minimum of 15 years of age at diagnosis were considered in this study. OCS is an observational study of HIV-infected people in Ontario, Canada \[[@r37], [@r38]\].

There were 2345 participants from the HAART era in the OCS. Of them, 1155 individuals had CD4+ counts available at baseline (within 3 months of first HIV+ date). In the current study, ADI was used as the survival endpoint/outcome, which was identified by the occurrence of OIs \[[@r6]\]. OIs are relatively uncommon among people who have CD4+ counts \> 500 cells/mm^3^ \[[@r5]\]. Hence, to maintain homogeneity among study participants in terms of immunological characteristics, only individuals with baseline CD4+ counts less than or equal to 500 cells/mm^3^ were included in the study. At baseline, 825 individuals had CD4+ counts ≤ 500 cells/mm^3^. However, three of these participants had both a cancer AIDS and a non-cancer AIDS diagnosis made at the same visit; as survival analysis of completing risks requires time to first outcome, these subjects were excluded. Therefore, the final study population consisted of 822 adult individuals who were diagnosed between January 1997 and October 2012. The maximum and median follow-up times were 16 years and 6.2 years, respectively. A total of 16,593 CD4+ counts measurements were observed, with a median of 18 measurements. The covariate "HIV risk category" was categorized into two major groups: MSM (MSM and MSM-IDU \[injection drug users\] combined) and others. Participants' demographic and clinical characteristics are presented in Table **[1](#T1){ref-type="table"}**.

2.2. Survival Endpoints {#sec2.2}
-----------------------

The AIDS-defining illness either with AIDS-defining cancer (cancer AIDS) or another clinical AIDS-defining event (non-cancer AIDS) was considered as the survival event. As one event can change the likelihood of observing the other event, they were treated as event of interest/competing event in this study \[[@r15], [@r28], [@r39]\]. When cancer AIDS was the main event of interest then non-cancer AIDS was considered as a competing risk, and vice versa. There were no patients with cervical cancer in our study data. Hence, the cancer AIDS only included patients with KS or NHL. All other ADI defined by the CDC \[[@r6]\] were considered as non-cancer AIDS. Subsequent ADI diagnoses that arose after the first ADI diagnosis were not considered to be events in this analysis. Therefore, for analysis, a patient could develop either cancer AIDS or non-cancer AIDS (disjoint first event). Time-to-event was calculated from the HIV diagnosis date to the date of first ADI, death, or last visit.

2.3. Statistical Analysis {#sec2.3}
-------------------------

Mean and median were reported for continuous variables. Number and proportion were reported for categorical variables. We used the t-test or Wilcoxon non-parametric test to compare continuous variables between two groups. Chi-square test was used to compare categorical variables. Cox cause-specific hazard (CSH) and Kaplan-Meier analyses were used to perform survival analysis \[[@r40], [@r41]\]. Two survival outcomes (cancer AIDS and non-cancer AIDS) were considered as event of interest/competing risk in this study. In competing risks scenarios, the traditional approach to study the effect of a covariate on a particular cause of failure is to model the CSH function, generally using Cox CSH models \[[@r27], [@r42]\]. We applied joint modeling method to incorporate time-dependent outcome in the Cox CSH regression model.

Two joint models were fitted: (i) with CD4+ counts and cancer AIDS, (ii) with CD4+ counts and non-cancer AIDS. Linear mixed effect (LME) model with random intercept and random slope was used to model longitudinal CD4+ counts \[[@r43]\].

To normalize CD4+ counts, the square root of the CD4+ counts was used. For the 𝑖^𝑡ℎ^ subject, the following LME model (also regarded as a submodel) was considered for the square root of the 𝑗^𝑡ℎ^ CD4+ counts measurement:

$\sqrt{{CD4 +}_{ij}} = \beta_{0}{+ \beta}_{1}{Time}_{ij} + \beta_{2}{MSM}_{i} + \beta_{3}{Age}_{i} + \beta_{4}{Arv}_{i} + \beta_{5}{HepC}_{i} + b_{0i} + b_{1i}{Time}_{ij} + \varepsilon_{ij}$

where $\sqrt{{CD4 +}_{ij}}$ indicates the square root of the 𝑗^𝑡ℎ^ CD4+ counts measurement on the 𝑖^𝑡ℎ^ individual, 𝑗 = 1, 2, ..., 𝑚~𝑖~, 𝑖 = 1, 2, ..., 𝑛 and 𝜀~𝑖𝑗~ is the mutually independent measurement errors. We used the following Cox CSH models (submodels):

For cancer AIDS,

$h_{i1}\left( t \right) = h_{10}\left( t \right)exp\left\{ {\gamma_{11}{MSM}_{i} + \gamma_{12}{Age}_{i} + \gamma_{13}{Arv}_{i} + \gamma_{14}{HepC}_{i} + \alpha\left\{ {\beta_{10} + \beta_{11}{Time}_{ij} + \beta_{12}{MSM}_{i} + \beta_{13}{Age}_{i} + \beta_{14}{Arv}_{i} + \beta_{15}{HepC}_{i} + b_{10i} + b_{11i}{Time}_{ij}} \right\}} \right\},$

For non-cancer AIDS,

$h_{i2}\left( t \right) = h_{20}\left( t \right)exp\left\{ {\gamma_{21}{MSM}_{i} + \gamma_{22}{Age}_{i} + \gamma_{23}{Arv}_{i} + \gamma_{24}{HepC}_{i} + \alpha\left\{ {\beta_{20} + \beta_{21}{Time}_{ij} + \beta_{22}{MSM}_{i} + \beta_{23}{Age}_{i} + \beta_{24}{Arv}_{i} + \beta_{25}{HepC}_{i} + b_{20i} + b_{21i}{Time}_{ij}} \right\}} \right\},$

where $h_{10}\left( t \right)$ and $h_{20}\left( t \right)~$are the unspecified baseline cause-specific hazards for cancer AIDS and non-cancer AIDS, respectively and $\alpha$ is the regression coefficient for the true CD4+ count (also regarded as association parameter between CD4+ counts and survival outcome).

The **JM** package in R was used to fit joint models \[[@r44]\]. Other analyses were done using SAS 9.4 (SAS Institute Inc., Cary, NC, U.S.A.). The level of significance was set at 0.05.

3.. RESULTS {#sec3}
===========

3.1.. Descriptive Analysis {#sec3.1}
--------------------------

Of a total of 822 participants, 657 (79.9%) were males, 103 (12.5%) were Hepatitis C virus-infected, and 686 (83.5%) were exposed to anti-retroviral (ARV) medications at some time in their care (Table **[1](#T1){ref-type="table"}**). The majority of participants were white (55.0%), followed by Black/African (19.2%). In the HIV risk category, the majority were MSM (MSM and MSM-IDU, 58.5%), 17.4% had previously resided in an HIV-endemic area, and 10.3% were heterosexual. Participants' mean age was 37.4 years (SD = 10.3) at the time of HIV diagnosis. At baseline, the mean CD4+ count was 260 cells/mm^3^ (SD = 145) and the mean log~10~ viral load was 4.5 copies/mL (SD = 0.9). The median follow-up time of the study was 6.2 years (interquartile range = 7.2). Among 822 individuals, 22(2.7%) developed cancer-related AIDS and 123 (15.0%) developed non-cancer AIDS. The incidence rate of cancer AIDS was 4.2 per 1,000 person-years \[95% Confidence Interval (CI): (2.7, 6.3)\] and the incidence rate of non-cancer AIDS was 23.3 per 1,000 person-years \[95% CI: (19.5, 27.8)\]. These values are similar to the findings of other studies (14-17).

### 3.1.1. Men Who Have Sex With Men (MSM) {#sec3.1.1}

Compared with all other ethnicities, white individuals were significantly more likely to be MSM (33.7% *vs.* 70.1%; *P* \< 0.0001) (Table **[2](#T2){ref-type="table"}**). The mean baseline CD4+ count and Log~10~ HIV viral load were significantly higher for MSM compared to all other HIV risk categories (275 cells/mm^3^ vs. 240 cells/mm^3^; *P* = 0.0008, 4.7 copies/mL vs. 4.3 copies/mL; *P* \< 0.0001, respectively). The proportion of ARV exposures ever was not different between the two groups (*P* = 0.38). Nonetheless, the proportion of hepatitis C virus (HCV) infection ever was significantly lower among MSM (6.7% vs. 20.8%; *P* \< 0.0001). Median follow-up time for MSM was significantly higher than that of the other group (6.5 vs. 5.8; *P* = 0.025) (Table **[2](#T2){ref-type="table"}**).

3.2. Kaplan-Meier Analysis {#sec3.2}
--------------------------

In the Kaplan-Meier analysis for the event of cancer AIDS, the time to cancer AIDS was significantly different between the two HIV risk categories (MSM and other) (Fig. **[1](#F1){ref-type="fig"}**). *P*s for Log-Rank and Wilcoxon tests were 0.032 and 0.047, respectively. Compared to MSM, the other risk group had better survival for cancer AIDS.

The Kaplan-Meier survival curves for the length of time after HIV infection until the occurrence of non-cancer AIDS are presented in [Fig. (**[2](#F2){ref-type="fig"}**)](#F2){ref-type="fig"}. There was a significant difference in survival times between MSM and other risk groups. *P*s for Log-Rank and Wilcoxon tests were 0.0004 and 0.0007, respectively. For non-cancer AIDS, MSM had better survival compared to the other risk group.

3.3. Cox Cause-Specific Hazards (CSH) Model {#sec3.3}
-------------------------------------------

In the univariable cause-specific hazards analysis, MSM had significantly higher hazards for cancer AIDS but significantly lower hazards for non-cancer AIDS compared to other HIV risk group \[HR = 3.07; *P* = 0.042, HR = 0.53; *P* = 0.0005\] (Table **[3](#T3){ref-type="table"}**). Older people had higher hazards for cancer AIDS. Age was not associated with noncancer AIDS. We were not able to estimate the effect of sex for cancer AIDS as no female participants had this outcome. Males had lower hazards for non-cancer AIDS. Individuals with ever use of ARV had significantly lower risk for both events. Ethnicity and hepatitis C infection were not associated with either of the events (Table **[3](#T3){ref-type="table"}**).

Covariates MSM, age, ever ARV, and ever Hep C infection were included in the multivariate Cox CSH models. Ethnicity was not included as it was highly correlated with MSM. In the multivariate CSH model for cancer AIDS, age, ever ARV were significant, but MSM was not (Table **[4](#T4){ref-type="table"}**). MSM was still significant in the multivariate model for non-cancer AIDS \[HR = 0.54; *P* = 0.0009\] (Table **[4](#T4){ref-type="table"}**).

3.4. Joint Model {#sec3.4}
----------------

MSM, age, and ever ARV were significant in the survival submodel for cancer AIDS (Table **[5](#T5){ref-type="table"}**). MSM and older participants had higher hazards of cancer AIDS. Participants with ever use of ARV had lower hazards of cancer AIDS. The association parameter was significantly different from zero, indicating a strong association between the square root of CD4+ counts and the risk for cancer. The negative value of the association parameter (0.17) indicated that the slope of CD4+ counts was negatively associated with the hazard for cancer AIDS, with a unit increase in this marker corresponded to a 16% decrease in the risk for cancer AIDS (HR = 0.84; *P* \<0.0001). MSM was not significant in the survival submodel for non-cancer AIDS (Table **[5](#T5){ref-type="table"}**). Age and ever ARV were significant. Older participants had higher hazards, while participants with ever use of ARV had lower hazards of non-cancer AIDS. The association parameter was significant; a unit increase in CD4+ counts corresponded to a 18% decrease in the risk for non-cancer AIDS (HR = 0.82; *P* \<0.0001).

Covariates MSM, time, age at diagnosis, ever ARV, and Hep C infection were significant in the longitudinal submodels for both cancer AIDS and non-cancer AIDS (Table **[5](#T5){ref-type="table"}**). The mean CD4+ count was significantly higher for MSM, participants with ever use of ARV, and Hep C infection. CD4+ counts decreased with the increment of age at diagnosis.

Since the association parameter was highly significant in the joint models for cancer AIDS, and non-cancer AIDS, this provided strong evidence that both survival outcomes were associated with the longitudinal trajectory of CD4+ counts. In the multivariate Cox CSH model for cancer AIDS (Table **[4](#T4){ref-type="table"}**), MSM had a higher hazard of cancer AIDS but not significantly higher (HR = 2.92; *P* = 0.055). However, in joint analysis (Table **[5](#T5){ref-type="table"}**), MSM had significantly higher hazard of cancer AIDS (HR = 3.86; *P* = 0.013). In the multivariate Cox CSH model for noncancer AIDS (Table **[4](#T4){ref-type="table"}**), MSM had significantly lower hazard of non-cancer AIDS (HR = 0.54; *P* = 0.0009). Nevertheless, in joint analyses (Table **[5](#T5){ref-type="table"}**), MSM did not have significantly lower hazard of non-cancer AIDS (HR = 0.73; *P* = 0.10). Thus, the joint models, which incorporated the effect of time-varying biomarker, provided different results from the separate multivariate Cox CSH models.

4. DISCUSSION {#sec4}
=============

In our study of participants with lower CD4+ counts (≤ 500 cells/mm^3^) at baseline, MSM had significantly higher hazards for cancer-related AIDS. CD4+ count was associated with both cancer AIDS and non-cancer AIDS. Several studies reported that the incidence of KS and NHL has significantly decreased and that survival time from these cancers has been improved for most patients with the initiation of HAART \[[@r16], [@r45]\]. However, KS was frequently identified in MSM in a study by Gingues and Gill \[[@r16]\]. Suárez-García *et al.* \[[@r46]\] also observed higher risk of KS among MSM in their study. MSM also had higher hazards of NHL in work by Bohlius *et al.* \[[@r47]\]. Biggar *et al.* \[[@r48]\] found NHL and KS to be associated with severe depletion of CD4+ count. Thus the results of our study are consistent with other study findings.

According to Gingues and Gill \[[@r16]\] patients who do not present for HIV care after diagnosis and patients who do not receive antiretroviral therapy at the time of diagnosis are more likely to be diagnosed with AIDS-defining cancers. Clifford *et al.* \[[@r49]\] observed that the use of HAART might lower the risk of KS and NHL. Bonnet *et al.* \[[@r50]\] reported that patients with elevated HIV RNA levels for long periods may have a higher risk of NHL. In our study, the median log~10~ HIV RNA level at baseline was significantly higher among MSM compared to the other group (4.8 copies/mL vs. 4.4 copies/mL, respectively). Thus, higher HIV RNA levels could possibly make these individuals more vulnerable to cancer-related AIDS. Since ARV treatment can suppress the viral load to a low level, our results emphasize the significance of earlier ARV initiation for the MSM risk group.

Our study data is from a large cohort which includes three-quarters of all HIV-infected people in Ontario \[[@r38]\]. Given the size, this cohort is expected to be a representative sample of the HIV-infected population receiving HIV treatment in Ontario. MSM represent the largest proportion of all the HIV-infected people in Canada \[[@r4]\]; similarly, in our study, 481 (58.5%) participants were MSM. We recognize that participants voluntarily participated in this study and thus may be different from the rest of HIV-infected people in Ontario. Hence the study may have recruitment bias \[[@r38]\]. Another concern regarding our data is the lack of information regarding comorbidity. As such, were not able to adjust the effects of those covariates in the model.

We applied joint modeling with competing risks in this study. If we would consider simply one event (AIDS) instead of two competing events (cancer AIDS, non-cancer AIDS), we would not be able to study the fact that MSM has opposite effects on these two events. In addition, we incorporated time-varying biomarker CD4+counts into the CSH models using joint modeling. CD4+counts were highly associated with both events. If time-varying biomarkers and survival outcomes are associated, we should consider this association to estimate parameters correctly as well as to draw proper statistical inference about the covariates. After incorporating CD4+counts in the CSH models using joint modeling, statistical inferences for MSM were changed for both cancer AIDS and non-cancer AIDS. The extended/time-dependent Cox model is also used to include the effect of time-varying biomarker in the survival model \[[@r51]\]. However, this model has some limitations. The time-dependent Cox model assumes that time-dependent covariates can be predicted and they do not have any measurement error \[[@r24]\]. This model also assumes that the covariates change value at follow-up visits and are unchanged in between the visits \[[@r24]\]. For these reasons, we preferred to use joint modeling in this study rather than the time-dependent Cox model.

CONCLUSION
==========

In this study, based on joint modeling, it appeared that MSM had higher risk for cancer AIDS (KS or NHL) than the other risk group. However, for non-cancer AIDS, risks were not significantly different between MSM and the other risk group in the joint model. Higher viral load could possibly make MSM vulnerable to cancer AIDS. Thus, our findings suggest earlier ARV initiation and regular monitoring of HIV viral load and CD4+ count should be high priority for the MSM HIV risk group. Regular screening for cancer is also important in individuals with lower CD4+ counts (≤ 500 cells/mm^3^) in the MSM group. Routine HIV testing in individuals within this HIV risk group is also vital, as untreated HIV infection represents a significant risk for cancer AIDS.
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###### 

Demographics and clinical characteristics of the participants (N=822).

  **Variable**                                     **Number (%)**
  ------------------------------------------------ ----------------
  Male                                             657 (79.9%)
  Age at HIV positive date                         
  Mean (SD)                                        37.4 (10.3)
  Median (interquartile range)                     37.0 (14.0)
  Race                                             
  Multiple race                                    39 (4.7%)
  Black/African                                    158 (19.2%)
  South Asian                                      40 (4.9%)
  White                                            452 (55.0%)
  Other                                            95 (11.5%)
  Unknown                                          38 (4.6%)
  HIV risk category                                
  Men Sex Men (MSM)                                442 (53.8%)
  MSM-Injection Drug User (IDU)                    39 (4.7%)
  IDU                                              61 (7.4%)
  Clotting factor                                  6 (0.7%)
  Transfusion                                      7 (0.9%)
  HIV-endemic                                      143 (17.4%)
  Heterosexual transmission                        85 (10.3%)
  MTC mother to child transmission                 1 (0.1%)
  Occupational                                     1 (0.1%)
  NIR Non-identified risk                          37 (4.5%)
  Ever Hepatitis C infection                       103 (12.5%)
  Ever ARV                                         686 (83.5%)
  CD4+ counts (cells/mm^3^) at baseline            
  Mean (SD)                                        260 (145)
  Median (interquartile range)                     268 (240)
  Log~10~ HIV viral load (copies/mL) at baseline   
  Mean (SD)                                        4.5 (0.9)
  Median (interquartile range)                     4.6 (1.1)
  Follow-up time, median (interquartile range)     6.2 (7.2)

###### 

Demographic and clinical characteristics associated with MSM.

  --------------------------------------------------------------------------------------------------------------------
  **Covariates**                                   **HIV Risk Category**\   **HIV Risk Category**\   ***P* - value**
                                                   **(MSM)**\               **(Other)**\             
                                                   **(N = 481, 58.5%)**     **(N = 341, 41.5%)**     
  ------------------------------------------------ ------------------------ ------------------------ -----------------
  Ethnicity (White)                                70.1%                    33.7%                    \< 0.0001^a^

  Age in years                                                                                       

  Mean (SD^d^)                                     37.9 (10.3)              36.7 (10.3)              0.12^b^

  Median (IQR^e^)                                  37.0 (13.0)              36.0 (14.0)              

  Ever Hepatitis C infection                       32 (6.7%)                72 (20.8%)               \< 0.0001^a^

  Ever ARV                                         406 (84.4%)              280 (82.1%)              0.38^a^

  CD4+ count (cells/mm^3^) at baseline                                                               

  Mean (SD^d^)                                     275 (142)                240 (146)                0.0008^b^

  Median (IQR^e^)                                  293 (222)                240 (244)                

  Log~10~ HIV viral load (copies/mL) at baseline                                                     

  Mean (SD^d^)                                     4.7 (0.9)                4.3 (0.9)                \< 0.0001^b^

  Median (IQR^e^)                                  4.8 (1.1)                4.4 (1.0)                

  Follow-up time, median (IQR)                     6.5 (6.1)                5.8 (8.0)                0.025^c^
  --------------------------------------------------------------------------------------------------------------------

^a^Chi-square test; ^b^T-test; ^c^Wilcoxon test; ^d^Standard deviation; ^e^Interquartile range

###### 

Univariable Cox cause-specific hazards model.

                               **Event = Cancer AIDS**                       **Event = Non-cancer AIDS**                                      
  ---------------------------- ------------------------- ------------------- ----------------------------- -------------- ------------------- ----------
  MSM                          1.12 (0.55)               3.07 (1.04, 9.06)   0.042                         -0.63 (0.18)   0.53 (0.37, 0.76)   0.0005
  Age at diagnosis             0.05 (0.02)               1.05 (1.02, 1.09)   0.005                         0.01 (0.01)    1.01 (1.00, 1.03)   0.15
  Gender (Male)^d^                                                                                         -0.62 (0.20)   0.54 (0.37, 0.79)   0.001
  White ethnicity              0.53 (0.46)               1.70 (0.69, 4.16)   0.24                          -0.29 (0.18)   0.75 (0.53, 1.07)   0.11
  Ever ARV                     -1.92 (0.43)              0.15 (0.06, 0.34)   \<0.0001                      -1.98 (0.18)   0.14 (0.10, 0.20)   \<0.0001
  Ever Hepatitis C infection   -1.12 (1.02)              0.33 (0.04, 2.42)   0.27                          0.09 (0.26)    1.09 (0.66, 1.83)   0.73

^a^Standard error; ^b^Hazards ratio; ^c^Confidence interval; ^d^Unable to estimate HR for cancer AIDS as no female participants had cancer AIDS

###### 

Multivariate Cox cause-specific hazards model.

                               **Event = Cancer AIDS**                       **Event = Non-cancer AIDS**                                      
  ---------------------------- ------------------------- ------------------- ----------------------------- -------------- ------------------- ----------
  MSM                          1.07 (0.56)               2.92 (0.97, 8.76)   0.055                         -0.62 (0.19)   0.54 (0.37, 0.78)   0.0009
  Age at diagnosis             0.06 (0.02)               1.06 (1.02, 1.10)   0.002                         0.01 (0.01)    1.01 (1.00, 1.03)   0.12
  Ever ARV                     -2.06 (0.44)              0.13 (0.05, 0.30)   \<0.0001                      -1.96 (0.18)   0.14 (0.10, 0.20)   \<0.0001
  Ever Hepatitis C infection   -0.94 (1.04)              0.39 (0.05, 2.98)   0.36                          -0.14 (0.27)   0.87 (0.51, 1.47)   0.60

^a^Standard error; ^b^Hazards ratio; ^c^Confidence interval;

###### 

Joint modeling of longitudinal and survival outcomes.

                               **Event = Cancer AIDS**   **Event = Non-cancer AIDS**                                                                  
  ---------------------------- ------------------------- ----------------------------- --------------- ---------------------- ----------------------- -------------
  Intercept                    17.36 (0.21)              \<0.0001                      17.35 (0.20)    \<0.0001                                       
  Time                         0.95 (0.01)               \<0.0001                      0.95 (0.01)     \<0.0001                                       
  MSM                          1.64 (0.10)               \<0.0001                      1.63 (0.09)     \<0.0001                                       
  Age at diagnosis             -0.06 (0.001)             \<0.0001                      -0.05 (0.004)   \<0.0001                                       
  Ever ARV                     0.33 (0.13)               0.01                          0.32 (0.12)     0.01                                           
  Ever Hepatitis C infection   0.38 (0.13)               0.004                         0.37 (0.13)     0.004                                          
  **Survival submodel**        **Estimate (SE^a^)**      **HR^b^ (95% CI^c^)**         **P-value**     **Estimate (SE^a^)**   **HR^b^ (95% CI^c^)**   **P-value**
  MSM                          1.35 (0.55)               3.86 (1.32, 11.29)            0.013           -0.31 (0.19)           0.73 (0.50, 1.07)       0.104
  Age at diagnosis             0.06 (0.01)               1.06 (1.03, 1.09)             \<0.0001        0.02 (0.01)            1.02 (1.01, 1.03)       0.004
  Ever ARV                     -1.96 (0.45)              0.14 (0.06, 0.34)             \<0.0001        -1.85 (0.19)           0.16 (0.11, 0.23)       \<0.0001
  Ever Hepatitis C infection   -1.06 (1.03)              0.35 (0.05, 2.63)             0.36            -0.44 (0.27)           0.65 (0.38, 1.11)       0.11
  CD4+ count                   -0.17 (0.04)              0.84 (0.77, 0.91)             \<0.0001        -0.20 (0.02)           0.82 (0.80, 0.85)       \<0.0001

^a^Standard error; ^b^Hazards ratio; ^c^Confidence interval;

[^1]: Ontario HIV Treatment Network, Toronto, Ontario; Members of the research team are in the acknowledgments section
